Last reviewed · How we verify
NCT06205316
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 trial testing Antiandrogen Therapy in Biochemically Recurrent Prostate Carcinoma in 118 participants. Currently enrolling.
22 January 2030
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 118 |
| Start date | 22 January 2024 |
| Primary completion | 22 January 2030 |
| Estimated completion | 22 January 2030 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Antiandrogen Therapy — full drug profile →
- Biospecimen Collection — full drug profile →
- Hypofractionated Radiation Therapy — full drug profile →
- Positron Emission Tomography
- Stereotactic Body Radiation Therapy — full drug profile →
- Survey Administration
- Magnetic Resonance Imaging
Conditions studied
- Biochemically Recurrent Prostate Carcinoma — all drugs for Biochemically Recurrent Prostate Carcinoma →
- Oligometastatic Prostate Carcinoma — all drugs for Oligometastatic Prostate Carcinoma →
- Recurrent Prostate Adenocarcinoma — all drugs for Recurrent Prostate Adenocarcinoma →
- Stage IIB Prostate Cancer AJCC v8 — all drugs for Stage IIB Prostate Cancer AJCC v8 →
Sponsor
Mayo Clinic
Who can join
18 and older, male only, with Biochemically Recurrent Prostate Carcinoma or Oligometastatic Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumors cells and have fewer side effects. SBRT may work just as well as hypofractionated radiation therapy at treating patients with biochemically recurrent or oligometastatic prostate cancer, but with a shorter treatment time and possibly fewer side effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06205316
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Antiandrogen Therapy
Trials testing the same drug.
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
- NCT06244004 — FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, · Phase 2 · recruiting
- NCT05676463 — MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer · Phase 2 · terminated
- NCT04947254 — Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or · Phase 2 · recruiting
- NCT03649841 — Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients · Phase 2 · terminated
Other recruiting trials for Biochemically Recurrent Prostate Carcinoma
Currently open trials in the same condition.
- NCT07073794 — Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recu · Phase 2 · recruiting
- NCT06813898 — An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial · EARLY_PHASE1 · recruiting
- NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
- NCT06105918 — Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Bioch · Phase 1 · active not recruiting
- NCT05320406 — RElugolix VErsus LeUprolide Cardiac Trial · Phase 2 · active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06205316 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205316.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing